EDC for trials under 50 patients: Phase 1–2 scale, 21 CFR Part 11–aligned controls, and one platform without enterprise overhead.
21 CFR Part 11–aligned · HIPAA-aligned security · No credit card required
It is tempting to view a 15-patient or 25-patient study as too small to justify a formal EDC system. But the regulatory standards for data integrity do not have a minimum patient threshold. If your data will be included in an IND application, a clinical study report, or a partner due-diligence package, it must meet the same standards of auditability and integrity as data from a 5,000-patient Phase 3 trial. The most common compliance shortcut in very small studies is using spreadsheets or generic electronic forms for data capture. These tools lack audit trails (who changed what, when, and why), electronic signature capabilities, and role-based access controls. When a sponsor or regulatory agency reviews data from these systems, the inability to demonstrate data provenance and integrity can result in data being deemed unreliable—a finding that can delay regulatory applications and damage credibility with partners and investors. Capture provides the compliance infrastructure that very small studies need without the overhead associated with enterprise platforms. Every data entry is logged with a timestamp and user identity. Modifications include reason-for-change documentation. Electronic signatures are 21 CFR Part 11–aligned. And role-based access ensures that each team member can only perform actions appropriate to their study role. This compliance foundation is built into the platform, not bolted on as an afterthought.
Under-50-patient studies are typically run by very lean teams. A single coordinator may be responsible for screening, consenting, enrolling, and following all participants. The investigator may serve as both the scientific lead and the medical monitor. A part-time data manager may handle data review, query resolution, and export. In this environment, every tool and process must be as efficient as possible—there is no capacity for complex, multi-step workflows that are designed for large, specialized teams. Capture is designed with this operational reality in mind. The interface is clean and task-oriented: coordinators see their participants, upcoming visits, and outstanding tasks. Data entry follows the visit schedule, with forms presented in the order they need to be completed. Edit checks catch errors at the point of entry. Consent, CRF data, and safety reporting are all accessible from the same participant record. This streamlined experience means coordinators spend less time navigating the system and more time on the activities that directly support the study.
For teams running their first clinical study—whether a startup biotech with its first IND, an academic group launching an investigator-initiated trial, or a device company conducting a first-in-human study—the process of selecting and implementing an EDC system can feel overwhelming. Capture simplifies this by providing a structured, self-service path from protocol to production. You start in a free sandbox environment where you can build and test your study design: configure CRFs based on your protocol, set up the visit schedule, define roles, and create consent forms. You can iterate on the design, test data entry workflows, and verify edit checks without any production risk. When the study design is finalized and any required validation is complete, you promote the configuration to production and begin enrolling participants. For teams that need guidance, Capture provides documentation and onboarding support. For Enterprise clients running regulated studies, we provide the documentation needed to support sponsor validation, including IQ/OQ/PQ artifacts and UAT support. The goal is to make the path from protocol to first patient as smooth as possible, regardless of whether this is your first study or your fiftieth.
Overview
Trials with under 50 patients—early Phase 1, dose-escalation studies, pilot programs, feasibility assessments, and small proof-of-concept trials—represent some of the most resource-constrained clinical research programs. These studies are often the first human exposure for a new compound or device, making them simultaneously high-stakes and operationally lean. The investigator team may consist of a principal investigator, one or two coordinators, and a part-time data manager, all operating at a single site with tight timelines and limited budget. Despite their small size, under-50-patient trials carry the same regulatory expectations as larger programs. Every data entry must be attributable, legible, contemporaneous, original, and accurate (ALCOA). Electronic signatures must meet 21 CFR Part 11 requirements. Participant privacy must be protected under HIPAA-aligned security controls. And the audit trail must provide a complete, tamper-evident record of every action taken within the system. Using spreadsheets, paper forms, or generic survey tools for these studies creates compliance gaps that can surface during sponsor audits or regulatory inspections. Capture provides EDC, eConsent, ePRO, and safety in one platform with 21 CFR Part 11–aligned controls and HIPAA-aligned infrastructure. The platform is purpose-built for the operational reality of very small studies: quick to set up, simple to use, fully compliant, and affordable. Study builders configure CRFs, visit schedules, consent forms, and edit checks through the browser in days, not months. Coordinators enter data through a modern web interface that requires minimal training. And the integrated platform means every data type—consent records, CRF entries, patient-reported outcomes, and safety reports—lives in one system with one audit trail. For teams running their first clinical study or operating with minimal infrastructure, Capture provides a compliant, practical foundation that can grow with the program. The same platform that supports a 15-patient Phase 1a study can scale to a 200-patient Phase 2 without migration or system change.
Very small trials require audit trails, access controls, and data integrity for regulatory and sponsor review. The data from a 12-patient dose-escalation study or a 30-patient pilot directly informs decisions about whether to invest further in the program. Errors, gaps, or compliance issues at this stage can delay or derail the entire development pathway. Enterprise EDC platforms have minimum commitments, per-site or per-patient pricing floors, and implementation processes designed for much larger programs. For a 20-patient study, paying for an enterprise EDC license and waiting three months for implementation does not make economic or operational sense. Many enterprise vendors also prioritize their larger clients for support and development, leaving small study teams underserved. At the other end of the spectrum, free or low-cost tools that lack audit trails, electronic signatures, and access controls may seem practical for very small studies but create regulatory risk. Data captured in non-compliant systems may not be acceptable for regulatory submissions or may require extensive remediation before it can be used. This is particularly problematic for studies that are intended to support IND applications or generate data for partner discussions. Capture is built for early-phase and small trials: one platform, one audit trail, and controls aligned with 21 CFR Part 11 without enterprise overhead or minimum commitments. The platform bridges the gap between enterprise EDC and non-compliant alternatives, giving under-50-patient study teams the compliance infrastructure they need at a price and pace that fits their reality.
FAQ
Explore the platform with a free sandbox. No sales call required.